Synthetic berberine derivatives as potential new drugs
DOI:
https://doi.org/10.1590/s2175-97902020000318835Keywords:
Berberine, Natural product, Synthetic derivatives, Drug discovery, Product development, CollaborationAbstract
The modern process of new drug discovery and development is an exciting, yet a challenging, endeavor. Although it can result in significant financial income and meet the medical needs of patients, it ultimately may result in failure. To achieve a fast and successful new product discovery and development process, natural products which are evolutionarily optimized as drug-like molecules have gained great attention as better potential sources of new chemical entities. Historically, plant species containing berberine are used in various traditional phytotherapy. However, despite the various therapeutic effects it exerts, berberine is not yet developed into a drug product. Addressing the barriers that hinder its successful development and the efforts made to overcome them is thus crucial. The toxicological and pharmacokinetic properties of berberine are the main barriers towards its development into a marketed drug product. It has low aqueous solubility, poor absorption, fast metabolism, and wide tissue distribution which lead to low bioavailability limiting its clinical application. Synthetic berberine derivatives with improved properties are suggested as better alternatives for further development and future therapeutic application. Hence, this paper summarizes the preclinical research studies conducted in the last decade to reveal the therapeutic potential of synthetic berberine derivatives for the treatment of various diseases and hence achieve successful berberine-based drug development in the future. To exploit the value of natural products as a source of leads for the development of effective drugs, collaboration among the different discovery and development scientists is essential.
Downloads
References
Ahmed T, Gilani AH, Abdollahi M, Daglia M, Nabavi SF, Nabavi SM. Berberine and neurodegeneration: A review of literature. Pharmacol Rep. 2015;67(5):970-979.
Albring KF, Weidemuller J, Mittag S, Weiske J, Geroni MC, Lombardi P, et al. Berberine acts as a natural inhibitor of Wnt/β-catenin signaling-Identification of more active 13-arylalkyl derivatives. Biofactors. 2013;39(6):652-662.
Amritpal S, Sanjiv D, Navpreet K, Jaswinder S. Berberine: alkaloid with wide spectrum of pharmacological activities. J Nat Prod. (Gorakhpur) 2010;3:64-75.
Bagade A, Tumbigeremutt V, Pallavi G, Cardiovascular Effects of Berberine: A Review of the Literature. JRM. 2017;6(1):37-45.
Bahar M, Deng Y, Zhu X, He S, Pandharkar T, Drew ME, et al. Potent antiprotozoal activity of a novel semi-synthetic berberine derivative. Bioorg Med Chem Lett. 2011;21(9): 2606-2610.
Bateman J, Chapman RD, Simpson D. Possible toxicity of herbal remedies. Scot Med J. 1998;43(1):7-15.
Battu SK, Repka MA, Maddineni S, Chittiboyina AG, Avery MA, Majumdar S. Physicochemical characterization of berberine chloride: a perspective in the development of a solution dosage form for oral delivery. AAPS PharmScitech. 2010;11(3):1466-1475.
Birdsall TC, Kelly GS. Berberine: Therapeutic Potential of Alkaloid Found in Several Medicinal Plants. Altern Med Rev. 1997;2:94-103.
Chen J, Cao J, Fang L, Liu B, Zhou Q, Sun Y, et al. Berberine derivatives reduce atherosclerotic plaque size and vulnerability in apoE-/- mice. J.Transl.Med. 2014;12(1): 326-339.
Chen YY, Li RY, Shi MJ, Zhao YX, Yan Y, Xu XX, et al. Demethyleneberberine alleviates inflammatory bowel disease in mice through regulating NF-κB signaling and T-helper cell homeostasis. Inflamm Res. 2017;66(2):187-196.
Cheng M, Liu R, Wu Y, Gu P, Zheng L, Liu Y, et al. LC-MS/MS determination and urinary excretion study of seven alkaloids in healthy Chinese volunteers after oral administration of Shuanghua Baihe tablets. J Pharm Biomed Anal. 2016;118:89-95.
Ckless k, Schlottfeldt JI, Pasqual M, Moynat P, Henrlquesf JAP, Wajner M. Inhibition of in-vitro lymphocyte transformation by the isoquinoline alkaloid berberine. J Pharm Pharmacol. 1995;47(12A):1029-1031.
Cragg GM, Newman DJ. Natural products: A continuing source of novel drug leads. Biochim Biophys Acta. 2013;1830:3670-3695.
Deng X, Zhao X, Han J, Wang J, Huang W, Qian H, et al. Synthesis and biological evaluation of berberine derivatives as IBS modulator. Lett Drug Des Discov. 2012;9(5):489-493.
Duraes F, Pinto M, Sousa E. Old Drugs as New Treatments for Neurodegenerative Diseases. Pharmaceuticals. 2018;11(2):44.
Feng R, Shou JW, Zhao ZX, He CY, Ma C, Huang M, et al. Transforming berberine into its intestine-absorbable form by the gut microbiota. Sci Rep. 2015; 5: 12155.
Franceschin M, Cianni L, Pitorri M, Micheli E, Cacchione S, Frezza C, et al. Natural Aromatic Compounds as Scaffolds to Develop Selective G-Quadruplex Ligands: From Previously Reported Berberine Derivatives to New Palmatine Analogues. Molecules. 2018;23(6):1423.
Freile M, Giannin F, Sortino M, Zamora M, Juarez A, Zaccgino S, et al. Antifungal activity of aqueous extracts and of berberine isolated from Berberis heterophylla. Acta Farm. Bonaerense. 2006;25(1):83-88.
Fung FY, Linn YC. Developing traditional Chinese medicine in the era of evidence-based medicine: current evidences and challenges. Evid Based Complement Alternat Med. 2015;2015:1-9.
Gao WW, Gopala L, Bheemanaboina YRR, Zhang GB, Li S, Zhou CH, et al. Discovery of 2-aminothiazolyl berberine derivatives as effective antibacterial agents toward clinically drug-resistant Gram-negative Acinetobacter baumanii. Eur J Med Chem. 2018;146:15-37.
Gibson M. Pharmaceutical Preformulation and Formulation Second Edition. A Practical Guide from Candidate Drug Selection to Commercial Dosage Form. 2. New York: Informa Healthcare USA; 2009.
Guaman Ortiz LM, Croce AL, Aredia F, Sapienza S, Fiorillo G, Syeda TM, et al. Effect of new berberine derivatives on colon cancer cells. Acta Biochim Biophys Sin (Shanghai). 2015;47(10):824-833.
Guaman Ortiz LM, Tillhon M, Parks M, Dutto I, Prosperi E, Savio M, et al. Multiple effects of berberine derivatives on colon cancer cells. Biomed Res Int. 2014;2014:1-12.
Guo Y, Li F, Ma X, Cheng X, Zhou H, Klaassen CD. CYP2D plays a major role in berberine metabolism in liver of mice and humans. Xenobiotica. 2011;41(11):996-1005.
Habtemariam S. Berberine and inflammatory bowel disease: A concise review. Pharmacol Res. 2016;113:592-599.
Haj-allahyari S. Maghsoudi, Hossein. Suppression of Proinflammatory cytokine gene expression with Aqueous Extract of Berberin. IJCRR. 2018;9(03):20224-20238.
Han Y, Kim MJ, Lee KY. Berberine derivative, Q8, stimulates osteogenic differentiation. Biochem Biophys Res. Commun. 2018;504(1):340-5.
Ho YT, Lu CC, Yang JS, Chiang JH, Li TH, Ip SW, et al. Berberine-induced apoptosis via promoting the expression of caspase-8,-9 and-3, apoptosis-inducing factor and endonuclease G in SCC-4 human tongue squamous carcinoma cancer cells. Anticancer Res. 2009;29(10):4063-4070.
Hua W, Ding L, Chen Y, Gong B, He J, Xu G. Determination of berberine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry. J Pharma Biomed Anal. 2007;44(4):931-7.
Huang L, Luo Z, He F, Lu J, Li X. Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010;18(12):4475-4484.
Huang MY, Lin J, Huang ZJ, Xu HG, Hong J, Sun PH, et al. Design, synthesis and anti-inflammatory effects of novel 9-O-substituted-berberine derivatives. MedChemComm. 2016;7(4):658-666.
Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res. 2008;22(8):999-1012.
Inbaraj JJ, Kukielczak BM, Bilski P, Sandvik SL, Chignell CF. Photochemistry and photocytotoxicity of alkaloids from Goldenseal (Hydrastis canadensis L.) 1. Berberine. Chem Res Toxicol. 2001;14(11):1529-34.
Jagetia GC. Isoquinoline alkaloid berberine exerts its antineoplastic activity by inducing molecular DNA damage in HeLa cells: A comet assay study. Biol Med. 2015;7(1):1.
Jahnke GD, Price CJ, Marr MC, Myers CB, George JD. Developmental toxicity evaluation of berberine in rats and mice. Birth Defects Res B Dev Reprod Toxicol. 2006;77(3):195-206.
Jeyakkumar P, Zhang L, Avula SR, Zhou CH. Design, synthesis and biological evaluation of berberine-benzimidazole hybrids as new type of potentially DNA-targeting antimicrobial agents. Eur. J Med Chem. 2016;122:205-15.
Jin X, Yan TH, Yan L, Li Q, Wang RL, Hu ZL, et al. Design, synthesis, and anticancer activity of novel berberine derivatives prepared via CuAAC “click” chemistry as potential anticancer agents. Drug Des Devel Ther. 2014;8:1047-1059.
Kaboli PJ, Ismail P, Ling KH. Molecular modeling, dynamics simulations, and binding efficiency of berberine derivatives: A new group of RAF inhibitors for cancer treatment. PloS One. 2018;13(3):e0193941.
Kim N, Park J, Gadhe CG, Cho SJ, Oh Y, Kim D, et al. A Protoberberine derivative HWY336 selectively inhibits MKK4 and MKK7 in mammalian cells: The importance of activation loop on selectivity. PloS One . 2014;9(4):e91037.
Kumar A, Ekavali, Chopra K, Mukherjee M, Pottabathini R, Dhull DK. Current knowledge and pharmacological profile of berberine: an update. Eur J pharmacol. 2015;761:288-297.
Kwon M, Choi YA, Choi MK, Song IS. Organic cation transporter-mediated drug-drug interaction potential between berberine and metformin. Arch. Pharmacal Res. 2015;38(5):849-56.
Li D, Zhang Y, Liu K, Zhao Y, Xu B, Xu L, et al. Berberine inhibits colitis-associated tumorigenesis via suppressing inflammatory responses and the consequent EGFR signaling-involved tumor cell growth. Lab Invest. 2017;07(11):1343.
Li XY, Zhao ZX, Huang M, Feng R, He CY, Ma C, et al. Effect of Berberine on promoting the excretion of cholesterol in high-fat-diet-induced hyperlipidemic hamsters. Transl Med. 2015;13(1):278-286.
Li Z, Geng YN, Jiang JD, Kong WJ. Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evid Based Complement Alternat Med . 2014;2014:1-12.
Lin JP, Yang JS, Chang NW, Chiu TH, Su CC, Lu KW, et al. GADD153 mediates berberine-induced apoptosis in human cervical cancer Ca ski cells. Anticancer Res . 2007;27(5A):3379-3386.
Ling YA, Ling-Ling WU, Qian LI, Qin-Mei HU, ZHANG SY, Kang LI, et al. Novel berberine derivatives: Design, synthesis, antimicrobial effects, and molecular docking studies. CJNM. 2018; 16(10): 0774-0781.
Linn YC, Lu J, Lim LC, Sun H, Sun J, Zhou Y, et al. Berberine-induced haemolysis revisited: safety of Rhizoma coptidis and cortex phellodendri in chronic haematological diseases. Phytother. Res. 2012;26(5):682-6.
Liu Y, Hao H, Xie H, Lv H, Liu C, Wang G. Oxidative demethylenation and subsequent glucuronidation are the major metabolic pathways of berberine in rats. J Pharm Sci. 2009;98(11):4391-401.
Liu Y, Hao H, Xie H, Lai L, Wang Q, Liu C, et al. Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug Metab Dispos. 2010;38(10):1779-1784.
Ma JY, Feng R, Tan XS, Ma C, Shou JW, Fu J, et al. Excretion of berberine and its metabolites in oral administration in rats. J Pharm Sci . 2013;102(11):4181-92.
Ma Y, Ou TM, Tan JH, Hou JQ, Huang SL, Gu LQ, et al. Synthesis and evaluation of 9-O-substituted berberine derivatives containing aza-aromatic terminal group as highly selective telomeric G-quadruplex stabilizing ligands. Bioorg Med Chem Lett . 2009;19(13):3414-3417.
Mahapatra A, Maheswari V, Kalia NP, Rajput VS and Khan IA. Synthesis and antitubercular activity of berberine derivatives. Chem Nat Compd. 2014;50(2):321-325.
Marin-Neto JA, MD, Sci D, Maciel Bc, MD, Secches AL, et al. Cardiovascular effects of berberine in patients with severe congestive heart failure. Clin. Cardiol. 1988;11(4):253-260.
Mistry B, Patel RV, Keum YS, Kim DH. Synthesis of N-Mannich bases of berberine linking piperazine moieties revealing anticancer and antioxidant effects. Saudi J Biol sci. 2017;24(1):36-44.
Mistry B, Patel RV, Keum YS, Noorzai R, Gansukh E, Kim DH. Synthesis of Mannich base derivatives of berberine and evaluation of their anticancer and antioxidant effects. J Chem Res. 2016; 40(2): 73-77.
Nechepurenko IV, Salakhutdinov NF, Tolstikov GA. Berberine: Chemistry and biological activity. CSD. 2010; 18:1-23.
Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod. 2016; 79(3): 629-661.
Pandey P, Doerksen RJ. New drugs from natural products around the world. Pharm Sci. 2016;22(4):215.
Pierpaol E, Arcamone AG, Buzzetti F, Lombardi P, Salvatore C, Provinciali M. Antitumor effect of novel berberine derivatives in breast cancer cells. Biofactors . 2013;39(6): 672-679.
Pongkittiphan V, Chavasiri W, Supabphol R. Antioxidant effect of berberine and its phenolic derivatives against human fibrosarcoma cells. Asian Pac J Cancer Prev. 2015;16(13): 5371-5376.
Qiang X, Xu L, Zhang P, Zhang Y, Zhou H, et al. Demethyleneberberine Attenuates Free Fatty Acid-And High Fat Diet-Induced Hepatic Lipotoxicity By Activating AMP-Activated Protein Kinase. FASEB J. 2015;29(1suppl):885-7.
Rad SZK, Rameshrad M, Hosseinzadeh H. Toxicology effects of Berberis vulgaris (barberry) and its active constituent, berberine: a review. Iran J Basic Med Sci. 2017;20(5):516-29.
Raza A, Aslam B, Naseer MU, Ali A, Majeed W, Hassan- SU. Antitumor activity of berberine against breast cancer: a review. Int. Res. J. Pharm. 2015;6(2):81-85.
Ren G, Wang YX, Li YH, Song DQ, Kong WJ, Jiang JD. Structure-activity relationship of berberine derivatives for their glucose-lowering activities. Int J Clin Exp Med. 2017;10(3):s5054-5060.
Ribaudo G, Zanforlin E, Canton M, Bova S, Zagotto G. Preliminary studies of berberine and its semi-synthetic derivatives as a promising class of multi-target anti-parkinson agents. Nat Prod Res. 2018;32(12):1395-1401.
Roselli M, Cavalluzzi MM, Bruno C, Lovece A, Carocci A, Franchini C, et al. Synthesis and evaluation of berberine derivatives and analogs as potential antiacetylcholinesterase and antioxidant agents. Phytochem Lett. 2016;18:150-156.
Shen B. A new golden age of natural products drug discovery. Cell. 2015;163(6):1297-1300.
Siddiqui AA, et al., Iram F, Siddiqui S, Sahu K. Role of natural products in drug discovery process. Int J Drug Dev Res. 2014;6(2):172-204.
Singh IP, Mahajan S. Berberine and its derivatives: a patent review (2009-2012). Expert Opin Ther Pat. 2013;23(2): 215-31.
Sun N, Chan FY, Lu YJ, Neves MAC, Lui HK, Wang Y, et al. Rational Design of berberine-based FtsZ inhibitors with broad-spectrum antibacterial activity. PloS One . 2014;9(5):e97514.
Tan XS, Ma JY, Feng R, Ma C, Chen WJ, Sun YP, et al. Tissue distribution of berberine and its metabolites after oral administration in rats. PloS One . 2013;8(10):e77969.
Tillhon M, Ortiz LM, Lombardi P, Scovassi AI. Berberine: new perspectives for old remedies. Biochem Pharmacol. 2012;84(10):1260-7.
Turner N, Li JY, Gosby A, To SWC, Cheng Z, Miyoshi H, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes. 2008;57(5):1414-1418.
Wang K, Feng X, Chai L, Cao S, Qiu F. The metabolism of berberine and its contribution to the pharmacological effects. Drug Metab Rev. 2017; 49(2):139-157.
Wang Y, Fu H, Li Y, Jiang J, Song D. Synthesis and biological evaluation of 8-substituted berberine derivatives as novel anti-mycobacterial agents. Acta Pharm Sin B. 2012;2(6): 581-587.
Wang Y, Fu X, Xu J, Wang Q, Kuang H. Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome. Sci Rep . 2016;6:28089.
Wang Y, Zhao Z, Yan Y, Qiang X, Zhou C, Li R, et al. Demethyleneberberine protects against hepatic fibrosis in mice by modulating NF-κB signaling. Int J Mol Sci. 2016;17(7):1036-1051.
Wang YX, Liu L, Zeng QX, Fan TY, Jiang JD, Deng HB, et al. Synthesis and identification of novel berberine derivatives as potent inhibitor against TNF-α-induced NF-κB activation. Molecules . 2017;22(8):1257-1271.
Wang YX, Pang WQ, Zeng QX, Deng ZS, Fan TY, Jiang JD, et al. Synthesis and biological evaluation of new berberine derivatives as cancer immunotherapy agents through targeting IDO1. Eur J Med Chem . 2018;143:1858-1868.
Xiao D, Liu Z, Zhang S, Zhou M, He F, Zou M, et al. Berberine derivatives with different pharmacological activities via structural modifications. Mini-Rev Med Chem. 2018;18(17):1424-41.
Xu L, Qiang X, Zhang Y. Demethyleneberberine attenuates isoniazid-induced-liver injury by reducing CYP2E1 expression and preventing endoplasmic reticulum stress. J Gastrointest Dig Syst. 2016;6(6suppl): 26.
Yang Z, Zhang Y, Chen X, Li W, Li GB, Wu Y, et al. Total Synthesis and Evaluation of B-Homo Palmatine and Berberine Derivatives as p300 Histone Acetyltransferase Inhibitors. Eur J Org. Chem. 2018;(8):1041-1052.
Yin J, Xing H, Yeb j. Efficacy of berberine in patients with type 2 diabetes mellitus. Metab Clin Exp. 2008;57(5): 712-717.
Zhang H, Wei J, Xue R, Wu JD, Zhao W, Wang ZZ, et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metab Clin Exp . 2010;59(2):285-292.
Zhang P, Qiang X, Zhang M, Ma D, Zhao Z, Zhou C, et al. Demethyleneberberine, a natural mitochondria-targeted antioxidant, inhibits mitochondrial dysfunction, oxidative stress, and steatosis in alcoholic liver disease mouse model. J Pharmacol Exp Ther. 2015;352(1):139-147.
Zou K, Li Z, Zhang Y, Zhang HY, Li B, Zhu WL, et al. Advances in the study of berberine and its derivatives: a focus on anti-inflammatory and anti-tumor effects in the digestive system. Acta Pharmacol Sin. 2017;38(2):157-167.
Zuo F, Nakamura N, Akao T, Hattori M. Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography ion trap mass spectrometry. Drug Metab Dispos . 2006;34(12): 2064-72.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.